Health economics in haemophilia: a review from the clinician's perspective.
about
Psychometric properties of the Greek Haem-A-QoL for measuring quality of life in Greek haemophilia patients.A zymogen-like factor Xa variant corrects the coagulation defect in hemophiliaCosts and utilization of treatment in patients with hemophilia.Phase 1 safety, tolerability, and pharmacokinetic study of single ascending doses of XM17 (recombinant human follicle-stimulating hormone) in downregulated healthy women.Healthcare expenditures for males with haemophilia and employer-sponsored insurance in the United States, 2008.Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII (AryoSeven™) and Activated Prothrombin Complex Concentrates (FEIBA™) to Treat Hemophilia A Patients with Inhibitors in Iran.Utilization patterns and associated costs of factor assistance programmes among persons with haemophilia: a single institution review.Octocog alfa, antihaemophilic factor (recombinant), plasma/albumin free method (Advate®): a review of its use in the management of patients with haemophilia A.How we use recombinant activated Factor VII in patients with haemophilia A or B complicated by inhibitors. Working group of hematology experts from Australia and New Zealand, Melbourne, April 2011.Rendering factor Xa zymogen-like as a therapeutic strategy to treat bleeding.Personalized prophylaxis in people with hemophilia A: challenges and achievements.Correction of human hemophilia A whole blood abnormalities with a novel bypass agent: zymogen-like FXa(I16L).Prevention of the musculoskeletal complications of hemophilia.Comparison of the effect of knee synovectomy in haemophilic patients with 153Sm- and 90Y-labelled hydroxyapatite 1 year after.On-demand treatment of bleeds in haemophilia patients with inhibitors: strategies for securing and maintaining predictable efficacy with recombinant activated factor VII.EQOFIX: a combined economic and quality-of-life study of hemophilia B treatments in France.Assessment of healthcare measures, healthcare resource use, and cost of care among severe hemophilia A patients in Mumbai region of India.An innovative outcome-based care and procurement model of hemophilia management.Population pharmacokinetics of recombinant factor VIII Fc fusion protein.The impact of extended half-life versus conventional factor product on hemophilia caregiver burden.Gene therapy in hemophilia A: a cost-effectiveness analysisBudget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective
P2860
Q33634745-76E1F805-B75E-4E79-BCC3-6DEDF643EF7BQ34149960-E9489A1D-9E4D-405B-B172-B8911FF282A4Q35821757-2839C177-D65B-4A2C-84F8-B249879E42AEQ35871759-B07795CE-5115-48BA-83A7-F907E1496C18Q35932549-01A31EBD-FA4F-4066-8B5A-E28041F5EE52Q37246445-1479C816-DCC2-4D4D-BF74-3C612E9DD43EQ37930707-408CF0C6-0B87-4D10-9F4D-3F8AD490F4F8Q38008021-26C30CDF-2616-4149-82BB-DD78C58389DCQ38060224-560F7297-22B6-47A6-95E8-93FB789F28D1Q38660256-A631A5E1-F504-40EC-914A-C7C82ECD80BEQ38997467-F956AAC8-5F10-4867-88D3-667E7D60A7C2Q40719779-5435C913-0E22-4DE0-A7F3-BE71E90365A9Q41887730-9FD94F7D-4D22-4BE7-AE89-A61A089A153FQ45865411-6B15027C-6B47-4463-8701-54B0AB1F8A9BQ45871901-3D6A5954-7727-4386-9290-DBAE09937B28Q45872775-60A66AB7-87E0-4DF9-B601-B3BD5639319EQ45873585-977EED76-8144-4B1F-B59D-8EEB780A2FB5Q45884983-C6099461-D0F1-4D38-B287-ADF7FEBDA30CQ45885620-7D96FCEF-F7D0-4108-B860-9AC06ECA7612Q47697767-47E86D73-1DAE-423C-92AD-FC8152C62FD1Q57083979-E4396AD1-47A1-4910-A3F5-D8E4917E2D87Q58803191-5006282F-68CC-459C-AE8A-61BBD8E26500
P2860
Health economics in haemophilia: a review from the clinician's perspective.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Health economics in haemophilia: a review from the clinician's perspective.
@en
Health economics in haemophilia: a review from the clinician's perspective.
@nl
type
label
Health economics in haemophilia: a review from the clinician's perspective.
@en
Health economics in haemophilia: a review from the clinician's perspective.
@nl
prefLabel
Health economics in haemophilia: a review from the clinician's perspective.
@en
Health economics in haemophilia: a review from the clinician's perspective.
@nl
P1433
P1476
Health economics in haemophilia: a review from the clinician's perspective.
@en
P2093
M A Escobar
P356
10.1111/J.1365-2516.2010.02257.X
P478
16 Suppl 3
P577
2010-05-01T00:00:00Z